AGN - AbbVie And Allergan Merger And Other News: The Good Bad And Ugly Of Biopharma
AbbVie (ABBV) reported that it has received conditional approval in Europe for its proposed merger with Allergan (AGN). The $63 billion merger has been closely watched by international regulatory authorities. It is likely that after Europe, the US may also give the green signal to the merger soon. However, the European approval has come with certain caveats.
The European Commission focused on investigating biologic treatments for ulcerative colitis and Crohn's disease. This is the area where there is overlap between AbbVie and Allergan. These diseases are collectively known as inflammatory bowel diseases or